Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP11B1 | P15538 | 3/20 | 0.38 |
| ▸ | CYP11B2 | P19099 | 3/20 | 0.38 |
| ▸ | HTR2A | P28223 | 2/20 | 0.34 |
| ▸ | TAAR1 | Q96RJ0 | 2/20 | 0.34 |
| ▸ | CYP2A6 | P11509 | 1/20 | 0.34 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.34 |
| ▸ | LOXL2 | Q9Y4K0 | 1/20 | 0.34 |
| ▸ | HDAC3 | O15379 | 1/20 | 0.34 |
| ▸ | HDAC6 | Q9UBN7 | 1/20 | 0.34 |
| ▸ | KIF11 | P52732 | 5/20 | 0.34 |
| ▸ | NOS1 | P29475 | 3/20 | 0.33 |
| ▸ | CHRNA7 | P36544 | 1/20 | 0.33 |
| ▸ | MLNR | O43193 | 1/20 | 0.31 |
| ▸ | NR1I2 | O75469 | 1/20 | 0.31 |
| ▸ | ADORA3 | P0DMS8 | 1/20 | 0.31 |
| ▸ | TBXA2R | P21731 | 1/20 | 0.31 |
| ▸ | CCKBR | P32239 | 1/20 | 0.31 |
| ▸ | OPRK1 | P41145 | 1/20 | 0.31 |
| ▸ | SLC6A3 | Q01959 | 1/20 | 0.31 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL10815632 | 0.83 | CYP11B1 (0.35) | CYP11B1CYP11B2HDAC3HDAC6KIF11 | |
| SCHEMBL9238225 | 0.81 | CYP11B1 (0.36) | CYP11B1CYP11B2HTR2ASMN1; SMN2HDAC3 | |
| SCHEMBL9234834 | 0.80 | HDAC3 (0.37) | CYP11B1CYP11B2HDAC3HDAC6NOS1 | |
| SCHEMBL3516047 | 0.80 | CYP11B1 (0.41) | CYP11B1CYP11B2HDAC3HDAC6NOS1 | |
| SCHEMBL8892954 | 0.80 | CYP11B1 (0.35) | CYP11B1CYP11B2HDAC3HDAC6NOS1 | |
| SCHEMBL8481796 | 0.80 | CYP11B1 (0.40) | CYP11B1CYP11B2HTR2ASMN1; SMN2HDAC3 | |
| SCHEMBL1765841 | 0.80 | CYP11B1 (0.40) | CYP11B1CYP11B2HTR2ASMN1; SMN2HDAC3 | |
| SCHEMBL10818578 | 0.79 | CYP11B1 (0.37) | CYP11B1CYP11B2HTR2ASMN1; SMN2HDAC3 | |
| SCHEMBL31317389 | 0.78 | NOS1 (0.38) | CYP11B1CYP11B2HDAC3HDAC6NOS1 | |
| SCHEMBL9235495 | 0.76 | CYP11B1 (0.37) | CYP11B1CYP11B2HTR2ASMN1; SMN2HDAC3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250161476-A1 | ANTIBODY-DRUG CONJUGATES COMPRISING GLP1 PEPTIDOMIMETICS AND USES THEREOF | REGENERON PHARMACEUTICALS, INC. (US) | 2025-05-22 | — | — | US | disclosed |
| US-12280124-B2 | Antibody-drug conjugates comprising GLP1 peptidomimetics and uses thereof | REGENERON PHARMACEUTICALS, INC. (US) | 2025-04-22 | — | — | US | disclosed |
| EP-4489855-A1 | ANTI-GLP1R ANTIBODY-DRUG CONJUGATES COMPRISING GLP1 PEPTIDOMIMETICS AND USES THEREOF | Regeneron Pharmaceuticals, Inc. (US) | 2025-01-15 | — | — | EP | disclosed |
| US-20230330254-A1 | ANTI-GLP1R ANTIBODY-TETHERED DRUG CONJUGATES COMPRISING GLP1 PEPTIDOMIMETICS AND USES THEREOF | REGENERON PHARMACEUTICALS, INC. (US) | 2023-10-19 | — | — | US | disclosed |
| WO-2023173132-A1 | ANTI-GLP1R ANTIBODY-DRUG CONJUGATES COMPRISING GLP1 PEPTIDOMIMETICS AND USES THEREOF | REGENERON PHARMACEUTICALS, INC. (US) | 2023-09-14 | — | — | WO | disclosed |
| CN-116615251-A | Antibody-drug conjugates comprising GLP1 peptide mimetics and the uses thereof | 瑞泽恩制药公司 | 2023-08-18 | — | — | CN | disclosed |
| EP-4210767-A1 | ANTIBODY-DRUG CONJUGATES COMPRISING GLP1 PEPTIDOMIMETICS AND USES THEREOF | Regeneron Pharmaceuticals, Inc. (US) | 2023-07-19 | — | — | EP | disclosed |
| US-20220096648-A1 | ANTIBODY-DRUG CONJUGATES COMPRISING GLP1 PEPTIDOMIMETICS AND USES THEREOF | REGENERON PHARMACEUTICALS, INC. (US) | 2022-03-31 | — | — | US | disclosed |
| WO-2022056494-A1 | ANTIBODY-DRUG CONJUGATES COMPRISING GLP1 PEPTIDOMIMETICS AND USES THEREOF | REGENERON PHARMACEUTICALS, INC. (US) | 2022-03-17 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20220096648-A1 | ANTIBODY-DRUG CONJUGATES COMPRISING GLP1 PEPTIDOMIMETICS AND USES THEREOF | GLP1R, GIPR, GCGR | CYP11B1 4123/4885CYP11B2 4552/4885HTR2A 946/4885 |
| US-20250161476-A1 | ANTIBODY-DRUG CONJUGATES COMPRISING GLP1 PEPTIDOMIMETICS AND USES THEREOF | GLP1R, GIPR, GCGR | CYP11B1 4123/4885CYP11B2 4552/4885HTR2A 946/4885 |
| US-12280124-B2 | Antibody-drug conjugates comprising GLP1 peptidomimetics and uses thereof | GLP1R, GIPR, GCGR | CYP11B1 4123/4885CYP11B2 4552/4885HTR2A 946/4885 |
| US-20230330254-A1 | ANTI-GLP1R ANTIBODY-TETHERED DRUG CONJUGATES COMPRISING GLP1 PEPTIDOMIMETICS AND USES THEREOF | GLP1R, GIPR, GCGR | CYP11B1 2492/4885CYP11B2 3696/4885HTR2A 2433/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.